IMMUTEP LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.43 AUD | -3.37% |
|
+11.69% | +24.64% |
| 03:03am | Canaccord Starts Immutep at Buy, Price Target is AU$1.00 | MT |
| Apr. 24 | Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck | MT |
Valuation
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 84.71 | 75.58 | 411.5 | 247.7 | 374 | 529 | - | - |
| Enterprise Value (EV) 1 | 75.79 | 58.31 | 350.9 | 169.2 | 251.4 | 453.9 | 467.4 | 483.7 |
| P/E ratio | -4.39 x | -4.61 x | -10.9 x | -7.65 x | -7.05 x | -11.7 x | -12.4 x | 16.1 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 11.3 x | 4.58 x | - | 36.7 x | 71.9 x | 166 x | 29.7 x | 3.21 x |
| EV / Revenue | 10.1 x | 3.53 x | - | 25 x | 48.3 x | 142 x | 26.2 x | 2.93 x |
| EV / EBITDA | -4.14 x | - | -20 x | -5.63 x | -6.65 x | -9.9 x | -11.2 x | 7.57 x |
| EV / FCF | -4.94 x | -5.37 x | -19.9 x | -5.59 x | -7.09 x | -9.66 x | -7.42 x | 4.96 x |
| FCF Yield | -20.2% | -18.6% | -5.03% | -17.9% | -14.1% | -10.4% | -13.5% | 20.2% |
| Price to Book | - | - | - | 2.62 x | 2.74 x | 5.3 x | 9.4 x | 4.32 x |
| Nbr of stocks (in thousands) | 338,860 | 487,631 | 748,153 | 854,123 | 1,187,306 | 1,188,835 | - | - |
| Reference price 2 | 0.2500 | 0.1550 | 0.5500 | 0.2900 | 0.3150 | 0.4450 | 0.4450 | 0.4450 |
| Announcement Date | 8/20/19 | 8/25/20 | 8/30/21 | 8/31/22 | 8/29/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Junio | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 7.489 | 16.5 | - | 6.758 | 5.2 | 3.191 | 17.82 | 164.8 |
| EBITDA 1 | -18.32 | - | -17.59 | -30.05 | -37.81 | -45.83 | -41.64 | 63.86 |
| EBIT 1 | -20.2 | -12.31 | -19.66 | -32.12 | -39.88 | -46.74 | -43.45 | 40.51 |
| Operating Margin | -269.66% | -74.61% | - | -475.26% | -766.83% | -1,464.55% | -243.77% | 24.58% |
| Earnings before Tax (EBT) 1 | -18.34 | -13.47 | -29.9 | -32.21 | -39.9 | -44.98 | -42.92 | 58.78 |
| Net income 1 | -18.34 | -13.47 | -29.9 | -32.21 | -39.9 | -44.58 | -42.57 | 22.8 |
| Net margin | -244.93% | -81.63% | - | -476.63% | -767.22% | -1,396.92% | -238.84% | 13.83% |
| EPS 2 | -0.0570 | -0.0336 | -0.0503 | -0.0379 | -0.0447 | -0.0379 | -0.0359 | 0.0277 |
| Free Cash Flow 1 | -15.33 | -10.86 | -17.66 | -30.25 | -35.44 | -47 | -63 | 97.5 |
| FCF margin | -204.66% | -65.81% | - | -447.65% | -681.49% | -1,472.79% | -353.47% | 59.16% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | 152.67% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 427.59% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 8/20/19 | 8/25/20 | 8/30/21 | 8/31/22 | 8/29/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: June | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 2.08 | 3.906 | - | 2.617 | 4.11 | 0.6667 |
| EBITDA 1 | - | - | -9.341 | -8.245 | -14.95 | -15.68 | - | - | - | -23.55 |
| EBIT 1 | -5.373 | -6.938 | -10.39 | -9.262 | -16.84 | -15.86 | -20.61 | -19.27 | -21.22 | -24.87 |
| Operating Margin | - | - | - | - | -809.62% | -405.89% | - | -736.14% | -516.19% | -3,729.98% |
| Earnings before Tax (EBT) 1 | -5.95 | -7.518 | -19.84 | -10.06 | -16.27 | -15.94 | -20.62 | -19.27 | -21.23 | -23.2 |
| Net income 1 | -5.95 | -7.518 | -19.84 | -10.06 | -16.27 | -15.94 | -20.62 | -19.27 | -21.23 | -23.67 |
| Net margin | - | - | - | - | -782.21% | -408.07% | - | -736.35% | -516.45% | -3,549.98% |
| EPS 2 | - | - | -0.0383 | -0.0120 | -0.0200 | -0.0185 | -0.0236 | - | -0.0179 | -0.0190 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/20/20 | 8/25/20 | 2/23/21 | 8/30/21 | 2/24/23 | 8/31/22 | 2/24/23 | 8/29/23 | 2/27/24 | - |
1AUD in Million2AUD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 8.93 | 17.3 | 60.6 | 78.5 | 123 | 75.1 | 61.7 | 45.4 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -15.3 | -10.9 | -17.7 | -30.3 | -35.4 | -47 | -63 | 97.5 |
| ROE (net income / shareholders' equity) | - | - | -56.1% | -38.5% | -34.6% | -48.1% | -104% | -34.6% |
| ROA (Net income/ Total Assets) | - | - | -46.5% | -35% | -32% | -44.2% | -127% | -137% |
| Assets 1 | - | - | 64.32 | 92.1 | 124.8 | 100.9 | 33.57 | -16.67 |
| Book Value Per Share 2 | - | - | - | 0.1100 | 0.1100 | 0.0800 | 0.0500 | 0.1000 |
| Cash Flow per Share 2 | - | - | -0.0300 | -0.0400 | -0.0400 | -0.0200 | -0.1000 | - |
| Capex 1 | 0.04 | 0.02 | 0.02 | 0.02 | 0.08 | 0.05 | 0.07 | 0.08 |
| Capex / Sales | 0.55% | 0.12% | - | 0.34% | 1.59% | 1.46% | 0.37% | 0.05% |
| Announcement Date | 8/20/19 | 8/25/20 | 8/30/21 | 8/31/22 | 8/29/23 | - | - | - |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.445
AUD
Average target price
0.978
AUD
Spread / Average Target
+119.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +24.64% | 347M | |
| +1.77% | 42.86B | |
| +46.96% | 41.36B | |
| +12.24% | 42.74B | |
| -8.83% | 27.68B | |
| +7.44% | 25.15B | |
| -23.01% | 18.63B | |
| +30.56% | 12.37B | |
| -1.82% | 11.92B | |
| +8.35% | 11.21B |
- Stock Market
- Equities
- IMM Stock
- Financials Immutep Limited
